IBDEI13V ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19506,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,19507,0)
 ;;=281.9^^105^1232^107
 ;;^UTILITY(U,$J,358.3,19507,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19507,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,19507,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,19507,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,19508,0)
 ;;=281.0^^105^1232^123
 ;;^UTILITY(U,$J,358.3,19508,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19508,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,19508,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,19508,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,19509,0)
 ;;=282.60^^105^1232^111
 ;;^UTILITY(U,$J,358.3,19509,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19509,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,19509,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,19509,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,19510,0)
 ;;=282.62^^105^1232^112
 ;;^UTILITY(U,$J,358.3,19510,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19510,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,19510,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,19510,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,19511,0)
 ;;=281.1^^105^1232^124
 ;;^UTILITY(U,$J,358.3,19511,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19511,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,19511,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,19511,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,19512,0)
 ;;=286.7^^105^1232^54
 ;;^UTILITY(U,$J,358.3,19512,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19512,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,19512,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,19512,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,19513,0)
 ;;=289.9^^105^1232^120
 ;;^UTILITY(U,$J,358.3,19513,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19513,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,19513,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,19513,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,19514,0)
 ;;=451.9^^105^1232^121
 ;;^UTILITY(U,$J,358.3,19514,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19514,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,19514,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,19514,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,19515,0)
 ;;=446.6^^105^1232^122
 ;;^UTILITY(U,$J,358.3,19515,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19515,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,19515,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,19515,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,19516,0)
 ;;=286.4^^105^1232^125
 ;;^UTILITY(U,$J,358.3,19516,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19516,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,19516,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,19516,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,19517,0)
 ;;=204.00^^105^1232^1
 ;;^UTILITY(U,$J,358.3,19517,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19517,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,19517,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,19517,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,19518,0)
 ;;=204.01^^105^1232^3
 ;;^UTILITY(U,$J,358.3,19518,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19518,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,19518,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,19518,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,19519,0)
 ;;=204.10^^105^1232^16
 ;;^UTILITY(U,$J,358.3,19519,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19519,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,19519,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,19519,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,19520,0)
 ;;=204.11^^105^1232^18
 ;;^UTILITY(U,$J,358.3,19520,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI13V
